VERAXA Biotech AG (NASDAQ: VRXA) is highlighting partnering opportunities for its proprietary BiTAC-ADC and BiTAC-TCE technology platforms ahead of the BIO International Convention, taking place June 22-25 in San Diego. The company recently reported new proof-of-concept data supporting its BiTAC-ADC platform, which is designed to improve cancer treatment precision through tumor-restricted activation of therapeutic agents while minimizing off-target toxicity.
VERAXA said the findings, together with previously presented BiTAC-TCE data unveiled at the American Association for Cancer Research Annual Meeting in April 2026, support the potential of two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both technologies at the BIO International Convention, scheduled for June 22-25, 2026, in San Diego.
The BiTAC platforms represent a significant advancement in antibody-based therapeutics. The BiTAC-ADC (antibody-drug conjugate) platform enables tumor-specific activation of cytotoxic agents, potentially reducing systemic toxicity common in traditional chemotherapy. The BiTAC-TCE (T-cell engager) platform is designed to direct T-cells to tumor cells, enhancing the immune system's ability to eliminate cancer. Both platforms are built on rigorous quality-by-design principles and stem from scientific breakthroughs at the European Molecular Biology Laboratory (EMBL).
VERAXA's pipeline includes multiple candidates in preclinical and clinical stages, targeting a range of solid tumors. The new proof-of-concept data for BiTAC-ADC demonstrate its ability to remain inert in circulation and become active only within the tumor microenvironment, which could improve the therapeutic window for patients. This approach addresses a key challenge in oncology: delivering potent therapies while sparing healthy tissues.
The company's presence at the BIO International Convention signals its commitment to advancing these platforms through strategic collaborations. VERAXA will engage with potential partners to explore licensing and co-development opportunities, leveraging its innovative technology to address unmet medical needs in oncology. For more details, the full press release is available at https://ibn.fm/1je4AA.
VERAXA Biotech AG is building a premier engine for next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company's technologies are powered by transformative platforms and guided by quality-by-design principles, rapidly advancing its pipeline into clinical development. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution for pioneering life science research.
Investors can find the latest news and updates on VRXA in the company’s newsroom at http://ibn.fm/VRXA. The BIO International Convention provides a key venue for VERAXA to showcase its platforms and attract partners, potentially accelerating the development of novel cancer therapies that could improve outcomes for patients with solid tumors.
